Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Xu, Yuming
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A	Completed	3	176	RoW	PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution	Tasly GeneNet Pharmaceuticals Co., Ltd	Charcot-Marie-Tooth Type 1A	03/24	03/24
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis	Recruiting	3	248	RoW	pimavanserin tartrate, placebo	Tasly Pharmaceutical Group Co., Ltd	Parkinson's Disease Psychosis	06/25	01/26
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)	Recruiting	2/3	132	RoW	B001, Placebo	Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd	Neuromyelitis Optica Spectrum Disorders	10/27	02/29
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders	Recruiting	2	162	RoW	BAT4406F Injection, BAT4406F Placebos	Bio-Thera Solutions	Optic Neuromyelitis Spectrum Disease	05/25	05/26